Valuation: Faeth Therapeutics, Inc.

Market Cap 860M 751M 705M 645M 1.21B 82.22B 1.21B 8.46B 3.27B 41.95B 3.23B 3.16B 135B P/E 2026 *
-1.45x
P/E 2027 * -10.1x
Enterprise Value 860M 751M 705M 645M 1.21B 82.22B 1.21B 8.46B 3.27B 41.95B 3.23B 3.16B 135B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.22%
Yield 2026 *
-
Yield 2027 * -
1 day+0.33%
1 week-14.56%
Current month+1.92%
1 month+4.38%
3 months+87.43%
6 months+5.83%
Current year+213.03%
1 week 32.11
Extreme 32.11
37.44
1 month 30.3
Extreme 30.3
42.14
Current year 8.37
Extreme 8.37
42.14
1 year 7.45
Extreme 7.45
42.14
3 years 5
Extreme 5
42.14
5 years 5
Extreme 5
238.4
10 years 5
Extreme 5
530
Manager TitleAgeSince
Chief Executive Officer 40 2026-06-12
Director of Finance/CFO 45 2026-06-12
Chief Operating Officer - 2026-08-13
Director TitleAgeSince
Chairman 62 2024-12-31
Director/Board Member 72 2014-12-31
Director/Board Member 51 2021-07-29
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Other

Director

42,631 0.1654%
9/11/26 Free

Director

25,000 0.0970%
7/21/26 Free

Chief Executive Officer

398,018 1.5440%
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%-14.56%+271.11%+103.66% 860M
-0.07%+5.66%+54.34%+113.69% 74.33B
-1.45%-1.43%+36.82%+80.62% 62.26B
-0.66%+7.14%+39.36%+29.20% 27.72B
-0.15%-3.58%-16.54%+358.69% 26.42B
+2.93%+2.03%+4.83%-5.22% 24.62B
+0.84%+7.70%+26.09%-10.70% 20.72B
+0.87%-2.52%+151.81%+328.17% 15.01B
+1.63%+3.45%+45.01%+169.46% 14.18B
+1.30%-7.06%-9.37%+835.52% 13.48B
Average +0.56%-0.82%+60.35%+200.31% 27.96B
Weighted average by Cap. +0.09%+2.04%+38.16%+150.53%

Financials

2026 *2027 *
Net sales - -
Net income -228M -199M -187M -171M -320M -21.77B -320M -2.24B -865M -11.11B -855M -837M -35.85B -104M -90.53M -84.95M -77.66M -146M -9.91B -146M -1.02B -393M -5.05B -389M -381M -16.31B
Net Debt - -
Logo Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
Employees
29
Date Price Change Volume
26-09-22 US$33.40 +0.33% 633,449
26-09-21 US$33.29 -3.51% 379,204
26-09-18 US$34.50 -1.79% 2,197,797
26-09-17 US$35.13 +2.60% 362,997
26-09-16 US$34.24 -3.19% 572,403
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
33.40USD
Average target price
56.67USD
Spread / Average Target
+69.66%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!